ArticleTranslational lung cancer research2025

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Haoran Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.